GT Biologics Set to Move Crohn’s Drug into Phase I
LONDON – GT Biologics Ltd. is poised to become a pioneer of the new drug class of live biotherapeutics after receiving orphan drug status from the FDA for Thetanix, a bacterial treatment for pediatric Crohn’s disease.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter